Skip to Content
Last Updated: 07/31/14

Current Funding Opportunities

The Requests for Applications (RFAs) and Program Announcements (PAs) listed below communicate CDP’s current funding opportunities and research interests. CDP staff contacts and published notices are provided in the summary link for each opportunity. We encourage you to discuss your proposed research with a CDP program director before you submit an application. This page updates to reflect the active Funding Opportunities.

To receive email updates, click here or follow us on Twitter.

NCI Exploratory/Developmental Research Grant Program: PAR-13-146 (NCI Omnibus R21)

Release Posted Date: March 19, 2013; Expiration Date: September 5, 2015
Application Receipt Dates: June 28, 2013; October 28, 2013; February 28, 2014; June 27, 2014; October 28, 2014; February 27, 2015; June 29, 2015, by 5:00 PM local time of applicant organization.

The NCI Exploratory/Developmental Grant (R21) funding opportunity supports exploratory and developmental research projects that could have a major impact in all areas of cancer research (basic, translational, clinical). The Cancer Diagnosis Program (CDP) specifically supports research programs to facilitate the development and validation of diagnostic markers and tests to improve outcomes for cancer patients. These studies may involve development of new biomarkers and innovative technologies that will lead to better tools for research and to aid clinical decision-making. The program also supports projects to improve cancer prognosis, predicting tumor progression and recurrence, and development of clinically useful markers to guide the treatment of cancer patients as well as to evaluate the response to treatment. CDP Contacts: Dr. Magdalena Thurin: 240-276-5973, thurinm@mail.nih.gov or Mr. Miguel Ossandon: 240-276-5714, ossandom@mail.nih.gov

Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials: PA-12-013 (R01) & PA-12-014(R21)

Release/Posted Date: November 16, 2011; Expiration Date: January 8, 2015
Application Receipt Dates: February 5, June 5, October 5 (R01) & February 16, June 16, October
16 (R21)

The objective of these FOAs is to invite research grant applications (R01 or R21) to perform validation of the clinical usefulness of new molecular diagnostics/assays that are becoming critical components for determining prognosis, predicting response to therapy and to guide the treatment of cancer patients. This program will support research studies that use tumor specimens collected from the NCI Clinical Trials Cooperative Groups or other large multi-institutional clinical trials linked to specific treatment and clinical outcome information. Contact: Dr. Magdalena Thurin, CDP, 240-276-5973, thurinm@mail.nih.gov or Dr. Minkyung (Min) Song, CTEP, 240-276-6139, songm@mail.nih.gov

Pilot Studies in Pancreatic Cancer: PA-11-297 (R21) & PA-11-298 (R03)

Release/Posted Date: Aug 9, 2011; Expiration Date: Jan 8, 2015
Application Receipt Dates: February 16, June 16, October 16

This PA aims to promote innovative research across multiple disciplines to better understand the etiology of pancreatic cancer and to facilitate its early detection, prevention, and treatment. Proposed projects may center on the biology, etiology, detection, prevention, and treatment of pancreatic cancer. This FOA focuses on pilot projects in early and conceptual stages that could provide a basis for more extended research. Contact: Dr.Mukesh Verma, DCCPS, (301) 594-7344, E-mail: vermam@mail.nih.gov; Dr.William C. Timmer DCTD, 240-276-6130, timmerw@mail.nih.gov

Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) PAR-13-169

Release/Posted Date: April 5, 2013; Expiration Date: May 8, 2016
Application Receipt Dates: February 5, June 5, October 5

This FOA encourages applications from research partnerships formed by academic and industrial investigators. The partnerships should establish an inter-disciplinary research team to work in strategic alliance to develop and translate in vivo imaging systems or support reference methods required to validate in vivo imaging systems on a targeted cancer problem. Contact: Dr. Houston Baker, CIP, 240-276-5908, bakerhou@mail.nih.gov; Dr. James A. Deye, 240-276-5690, deyej@mail.nih.gov or Mr. Miguel R. Ossandon, 240-276-5680, ossandom@mail.nih.gov.

Bioengineering Technologies

The NIH bioengineering program supports basic, applied, and translational bioengineering research that addresses important biological or medical research problems. CDP Contact: Mr. Miguel Ossandon: 240-276-5714, ossandom@mail.nih.gov

Exploratory/Developmental Bioengineering Research Grants [EBRG]: PA-12-284 (R21)

Release/Posted Date: October 14, 2009; Expiration Date: January 8, 2016
Application Receipt Dates: February 16, June 16, October 16

The EBRGs support early bioengineering research. EBRG applications may contain minimal or no preliminary data, and may propose hypothesis-driven, discovery-driven or design-directed research.

Bioengineering Research Grants [BRG]: PAR-13-137 (R01)

Release/Posted Date: October 14, 2009; Expiration Date: May 8, 2016
Application Receipt Dates: February 5, June 5, October 5

The BRGs support multi-disciplinary research performed in in a single laboratory or by multiple organizations. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.

Bioengineering Research Partnerships [BRP]: PAR-10-234 (R01)

Release/Posted Date: July 21, 2010; Expiration Date: January 8, 2014
Application Receipt Dates: February 5, June 5, October 5

The BRPs support large basic, applied, and translational multi-disciplinary research performed by multiple organizations that applies an integrative approach, which includes bioengineering and biomedical/clinical components.

The NCI Innovative Molecular Analysis Technologies (IMAT) Program (http://innovation.cancer.gov/)

Release/Posted Date: December 20, 2013; Expiration Date: September 19, 2014
Application Due Date(s): Feb 20, 2014; May 20, 2014, September 18, 2014

IMAT supports the development of next-generation analytical methodologies and tools that have the potential to revolutionize cancer research, prevention, detection, diagnostics and treatment. The IMAT program funds research in four areas:

Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research: RFA-CA-14-003 (R21)

The program funds studies proposing exploratory research projects focused on the inception and development of early stage, highly innovative, technologies or emerging technologies with significant transformative potential that has not yet been explored in a cancer-relevant use. CDP Contact: Dr. Brian Sorg, 240-276-5712, sorgbs@mail.nih.gov or Dr. Aniruddha Ganguly, 240-276-5905, aniruddha.ganguly@nih.gov

Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research: RFA-CA-14-004 (R33)

The program funds research projects on the advanced development of emerging molecular analysis technologies through technical/analytical validation in an appropriate cancer-relevant biological system or context. CDP Contact: Dr. Brian Sorg, 240-276-5712, sorgbs@mail.nih.gov

Early-Stage Development of Innovative Technologies for Biospecimen Science: RFA-CA-14-005 (R21)

The program funds research proposing technically innovative feasibility studies focused on early stage development of technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of cancer-relevant biospecimens or their derivatives. CDP Contact: Dr. Rodrigo Chuaqui, 240-276-5910, chuaquir@mail.nih.gov

Validation and Advanced Development of Emerging Technologies for Biospecimen Science: RFA-CA-14-006 (R33)

The program funds studies proposing technically innovative feasibility studies focused on the advanced development and validation of cancer-relevant technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or their derivatives. CDP Contact: Dr. Rodrigo Chuaqui, 240-276-5910, chuaquir@mail.nih.gov or Dr. Aniruddha Ganguly, 240-276-5905, aniruddha.ganguly@nih.gov.

FOR THE LATEST INFORMATION ABOUT NCI INITIATIVES, VISIT
Division of Extramural Activities, National Cancer Institute
http://deainfo.nci.nih.gov/funding.htm